QLGN

Qualigen Therapeutics (QLGN)

Qualigen Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:QLGN

1 2 3 4 5 6 7 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/15	05 : 05	Edgar (US Regulatory)	Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB	NASDAQ:QLGN	Qualigen Therapeutics Inc
2024/05/04	09 : 59	Edgar (US Regulatory)	Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]	NASDAQ:QLGN	Qualigen Therapeutics Inc
2024/04/16	20 : 00	GlobeNewswire Inc.	Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™	NASDAQ:QLGN	Qualigen Therapeutics Inc
2024/04/10	21 : 00	GlobeNewswire Inc.	Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting	NASDAQ:QLGN	Qualigen Therapeutics Inc
2024/04/09	21 : 00	GlobeNewswire Inc.	Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting	NASDAQ:QLGN	Qualigen Therapeutics Inc
2024/02/27	21 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:QLGN	Qualigen Therapeutics Inc
2024/02/23	06 : 10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:QLGN	Qualigen Therapeutics Inc
2023/12/08	06 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:QLGN	Qualigen Therapeutics Inc
2023/11/23	06 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:QLGN	Qualigen Therapeutics Inc
2023/11/15	06 : 30	GlobeNewswire Inc.	Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023	NASDAQ:QLGN	Qualigen Therapeutics Inc
2023/11/09	04 : 16	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:QLGN	Qualigen Therapeutics Inc
2023/11/07	22 : 30	GlobeNewswire Inc.	Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors	NASDAQ:QLGN	Qualigen Therapeutics Inc
2023/10/23	21 : 30	GlobeNewswire Inc.	Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer	NASDAQ:QLGN	Qualigen Therapeutics Inc
2023/10/17	21 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:QLGN	Qualigen Therapeutics Inc
2023/09/29	05 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:QLGN	Qualigen Therapeutics Inc
2023/09/27	21 : 30	GlobeNewswire Inc.	Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023	NASDAQ:QLGN	Qualigen Therapeutics Inc
2023/09/08	13 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:QLGN	Qualigen Therapeutics Inc
2023/09/02	05 : 15	Edgar (US Regulatory)	Form POS AM - Post-Effective amendments for registration statement	NASDAQ:QLGN	Qualigen Therapeutics Inc
2023/08/17	21 : 30	GlobeNewswire Inc.	Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors	NASDAQ:QLGN	Qualigen Therapeutics Inc
2023/08/15	23 : 04	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:QLGN	Qualigen Therapeutics Inc
2023/08/15	21 : 30	GlobeNewswire Inc.	Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023	NASDAQ:QLGN	Qualigen Therapeutics Inc
2023/08/15	05 : 16	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:QLGN	Qualigen Therapeutics Inc
2023/08/05	05 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:QLGN	Qualigen Therapeutics Inc
2023/08/01	21 : 35	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:QLGN	Qualigen Therapeutics Inc
2023/08/01	21 : 30	GlobeNewswire Inc.	Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors	NASDAQ:QLGN	Qualigen Therapeutics Inc
2023/07/27	06 : 25	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:QLGN	Qualigen Therapeutics Inc
2023/07/24	21 : 15	GlobeNewswire Inc.	Qualigen Therapeutics Divests FastPack® Diagnostics Business	NASDAQ:QLGN	Qualigen Therapeutics Inc
2023/07/14	06 : 29	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:QLGN	Qualigen Therapeutics Inc
2023/07/08	06 : 08	Edgar (US Regulatory)	Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]	NASDAQ:QLGN	Qualigen Therapeutics Inc
2023/06/27	06 : 25	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:QLGN	Qualigen Therapeutics Inc